Sage Therapeutics Inc (SAGE)
13.94
+0.84
(+6.37%)
USD |
NASDAQ |
May 03, 16:00
13.95
+0.01
(+0.07%)
After-Hours: 20:00
Sage Therapeutics Gross Profit Margin (Quarterly): 83.94% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 83.94% |
| December 31, 2023 | 98.95% |
| September 30, 2023 | 66.68% |
| June 30, 2023 | 91.71% |
| March 31, 2023 | 93.02% |
| December 31, 2022 | 95.01% |
| September 30, 2022 | 89.42% |
| June 30, 2022 | 86.68% |
| March 31, 2022 | 81.92% |
| December 31, 2021 | 94.70% |
| Date | Value |
|---|---|
| September 30, 2021 | 90.90% |
| June 30, 2021 | 90.99% |
| March 31, 2021 | 88.19% |
| December 31, 2020 | 99.99% |
| September 30, 2020 | 90.91% |
| June 30, 2020 | 89.90% |
| March 31, 2020 | 92.56% |
| December 31, 2019 | 88.83% |
| September 30, 2019 | 96.16% |
| June 30, 2019 | 94.96% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
66.68%
Minimum
Sep 2023
99.99%
Maximum
Dec 2020
90.27%
Average
90.95%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Biogen Inc | 76.33% |
| Perspective Therapeutics Inc | -- |
| Vanda Pharmaceuticals Inc | 92.36% |
| Ligand Pharmaceuticals Inc | 94.16% |
| ADMA Biologics Inc | 42.06% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -56.67% |
| Return on Assets | -51.31% |
| Return on Invested Capital | -56.67% |
| Profit Margin (Quarterly) | -1.37K% |
| Operating Margin (Quarterly) | -1.49K% |
| Return on Net Operating Assets | -1.34K% |